Product Overview
Stanozolol is a DHT-derived, 17-alpha-alkylated anabolic, and British Dragon supplies it for injection as Stanabol 50 Inj, a 50 mg per ml aqueous suspension in a 10 ml vial. The alkylation at carbon 17 is what makes the compound survive oral use and also what puts the liver under pressure; injecting a suspension avoids the first pass but not the hepatic stress, because the structural feature is unchanged. What the injection does change is the release profile: the aqueous depot empties more slowly than a tablet dissolves, and the half-life extends from roughly nine hours orally to about a day when injected.
The compound does not aromatize at all. There is no estradiol conversion, no fluid retention and no gynecomastia from stanozolol itself, which is why it belongs to cutting and conditioning phases rather than to mass work. Its effects are largely cosmetic in the sense that hardness, vascularity and a tighter look appear only where body fat is already low; on a high-fat physique the same dose produces very little visible change. Because the suspension is water-based it also behaves differently in the syringe, settling on standing and requiring a shake and a larger-gauge needle than an oil.
Stanozolol is never a base. It is added on top of a testosterone ester such as Testabol Depot, which supplies the androgen the compound does not, and it is frequently finished with a hardening injectable such as Mastabol 100. Estrogen control follows the testosterone base through Exemestane or Anastrozole, never through the Stanabol, since there is no aromatization to manage on the stanozolol side.
Dosage Protocol
The reference figures below come from the stanozolol sheet in this folder. The oral route carries the same active substance, so the numbers transfer between routes; only injection frequency and site tolerance differ.
| Entry level | 20-30 mg a day equivalent, run for no more than 6 weeks, because the hepatic load is present from the first dose |
| Established users | 40-50 mg a day equivalent over 6-8 weeks; split the total because the active life is short |
| Upper end | 50-60 mg a day orally, or about 50 mg every other day by injection, capped at around six weeks |
| Female | The only female reference found is a low oral dose of 5-10 mg a day for 4-6 weeks under close control; no separate female injection protocol is documented, and virilization risk remains |
| Administration | Intramuscular injection of a water-based suspension, given every other day; shake the vial, use a wider needle than for an oil, and rotate sites |
Suggested Protocols
Three uses cover almost every Stanabol cycle. In each one the stanozolol sits on top of a testosterone base and never replaces it.
What to Expect
- Fast start. The injected suspension is active within a day, and users often notice a tighter, harder look within the first one to two weeks.
- Conditioning. Vascularity and muscle separation improve noticeably when body fat is already low.
- No water. There is no fluid gain from the compound, so scale weight may stay flat while the look changes.
- Strength. A useful increase in strength without added body weight, which is why it suits a weight-class or conditioning phase.
- Joints. The dry profile can make existing joint discomfort more noticeable, especially alongside another non-aromatizing compound.
- Injection site. A water-based suspension is more likely to leave a sore, swollen spot than an oil, and the reaction can last a few days.
- Limit. Not a mass drug and not a base; it does not substitute for calories, and it should not be run for months.
Side Effects and Management
Stanozolol has no estrogenic profile, so the concerns are hepatic, lipid-related and androgenic rather than fluid or gynecomastia.
Post-Cycle Therapy
Stanozolol suppresses natural production despite not aromatizing, and the roughly one-day active life means the injection clears faster than a long testosterone ester.
